Merus N.V., a clinical-stage immuno-oncology company developing bispecific antibody therapeutics, and the Institute for Research in Biomedicine (IRB) Barcelona, a research center devoted to understanding fundamental questions about human health and disease, have entered a research collaboration to jointly develop novel agents that target the tumor microenvironment. The research collaboration will combine Merus’ Biclonics technology platform for the discovery and development of therapeutic bis...